| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Contrast Medium' found in 1 term [] and 26 definitions []
| previous 16 - 20 (of 27) nextResult Pages : [1] [2 3 4 5 6] | | | | Searchterm 'Contrast Medium' was also found in the following services: | | | | |
| | | | | Searchterm 'Contrast Medium' was also found in the following service: | | | | |
| | |
| |
|
A brand name for ferumoxide (same as Endoremâ„¢)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide. In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex.
Drug Information and Specification
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
CONCENTRATION
11.2mg Fe/ml
PREPARATION
Suspend in an isotonic glucose solution
DEVELOPMENT STAGE
For sale
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
| | | | • View the DATABASE results for 'Feridex®' (9).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Fluoroscopic Triggering' (2).
| | | | Further Reading: | Basics:
|
|
| |
| | | Searchterm 'Contrast Medium' was also found in the following services: | | | | |
| | |
| |
|
Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
Other MR contrast agents accumulate selectively in the hepatocytes, e.g.:
| | | | • View the DATABASE results for 'Intracellular Contrast Agents' (3).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'Contrast Medium' was also found in the following service: | | | | |
| | |
| |
|
Keyhole imaging is used for dynamic imaging with contrast medium. The advantage is that the keyhole technique increases temporal resolution without a loss of spatial resolution by limited data acquisition. Keyhole Fourier imaging updates the low spatial frequencies of the original full, high-resolution data set. The high spatial frequency content of the image is constant in time so that its updating would be unnecessary. The high spatial frequency data is acquired from a baseline image, for example, before injection of a contrast agent.
After contrast injection, only the lower spatial frequency data is acquired because, there is no change in the tissue that is responsible for the higher frequency spatial variation in the image. | | | | • View the DATABASE results for 'Keyhole' (8).
| | | • View the NEWS results for 'Keyhole' (1).
| | | | Further Reading: | Basics:
|
|
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |